

**2025 Annual General Meeting
Chair Address and Presentation**

Genetic Signatures Limited [ASX:GSS] (“**GSS**” or the “**Company**”) advises in accordance with ASX Listing Rule 3.13.3, a copy of the address by Chair, Caroline Waldron and slides to be presented at today’s Annual General Meeting are attached.

– END –

Announcement authorised for release by the Board of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter
Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited:

Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures’ proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

Chair's Address

Good morning Shareholders, Ladies and Gentlemen.

It is a pleasure to welcome you to the 2025 Annual General Meeting of Genetic Signatures Limited.

This past financial year, FY2025, has been a year of significant transformation for the Company. This has necessitated courageous decision-making by Management and the Board. There are two main areas where these changes are most evident – one in the strengthening of the Company's governance and two, in certain key operations. I will deal with each of these in turn, and our CEO will share with you highlights of the Company's performance during the year in her address.

You will all be aware that the most notable governance change over FY2025 has been in relation to our leadership.

To address the evolving needs of our Company, following a review of the Board's skills matrix, in the first quarter of FY2025 we appointed two experienced ASX directors, Ms Anne Lockwood and Dr Jenny Harry, to our Board. Subsequently as part of a planned transition, I was humbled to be appointed as Chair, succeeding Dr Nick Samaras, who ably led our Company for over 14 years. At the same time, we continue to have the unparalleled contributions of our US based directors Neil Gunn and Mike Aicher in our boardroom.

The result is that today the Board comprises a diverse group of commercially driven, highly credentialled, well-networked and accountable directors who bring a blend of continuity and fresh perspective to our strategic direction and decisions.

A leadership highlight in FY2025 was the appointment of Allison Rossiter as CEO in September 2024.

Together with the Board, Allison has led the Company's transformation journey and has brought to Genetic Signatures a strong commercial lens, disciplined approach to resource allocation, and commitment to simplification. Her ability to influence and unify the team has already delivered meaningful improvements across our people, processes, and products. Her leadership is energising the organisation and driving a culture of high performance and customer focus.

A key governance change has been establishing a Technology Committee to provide input into research and development programs and product roadmaps, ensuring alignment with the Company's strategic priorities and commercial objectives. The recent appointment of a Chief Technology Officer (CTO), skilled in converting technical innovation into market-ready products, strengthens leadership for implementing commercial strategy. Working with the CEO and CTO, the Committee advises the Board on technical matters and risks to support informed decision-making.

We also recognise the importance of effective communication with our shareholders. Through our broader engagement, we have taken deliberate steps to improve the clarity, transparency, and accessibility of our communications to ensure you are well-informed and connected to our progress.

Next, I would like to share some of our more operationally focused matters with you. Throughout the past financial year, the Board has collaborated closely with Management and endorsed several strategic decisions. These included sharpening our focus on core products, reorganising resources, and choosing to move away from developing an in-house automated instrument, opting instead to partner with established market leaders. These decisions, while tough, were made to enhance commercial outcomes and improve our operational efficiency.

In the U.S. market, although the uptake of our *EasyScreen*[™] Gastrointestinal Parasite Detection Kit is progressing slower than initially anticipated, we are optimistic about its long-term prospects. We have adjusted our go-to-market approach and realigned our resources to better position ourselves to translate this potential into tangible revenue. The Board remains committed to backing Management's initiatives to tap into this important growth market.

The importance of ESG and carbon emissions reporting continues to grow, and we are preparing accordingly. While the Company is not required to report until 30 June 2028, we are preparing for this transition. For example, we have taken proactive steps to validate eco-friendly packaging, as well as the planned introduction of smaller packaging formats for our products to minimise our environmental impact and align our operations with emerging best practices in sustainability for longer term success.

My Board colleagues and I acknowledge the decline in the Company's share price over the past year and understand your concerns. While this is not unusual during periods of transformation and a "whole of business reset", we firmly believe that the strategic changes made during the past year, particularly the renewed focus, fresh leadership, and operational improvements, are critical to the Company's long-term value creation.

Finally, but not least, I want to thank you, our shareholders, for your patience and continued support during the FY2025 year. Your trust has enabled us to make the necessary changes to set Genetic Signatures up for sustainable success. We look forward to building on this momentum and delivering on the exciting opportunities ahead.



2025 Annual General Meeting

17 November 2025



2025 Annual General Meeting AGENDA

1. Chair Address
2. CEO Presentation
3. Q&A / Voting Procedure Overview
4. Formal Business of the Meeting
5. General Questions





Genetic Signatures

Transforming
Molecular
Diagnostics



2025 Annual General Meeting

Chair Address – Caroline Waldron



Genetic Signatures

Transforming
Molecular
Diagnostics



2025 Annual General Meeting
CEO Presentation – Allison Rossiter



Watch Online →



“I would have loved access to a PCR test like this”



Challenge:

Gastroenteritis diagnosis was slow, fragmented, and often inconclusive.



Solution:

Adopted *EasyScreen*[™] Pan-Enteric Detection Kit for all inpatient and community stool samples.



Results:

- **Rapid Results** - 100% A&E cases had results within 5 hours
- **Better Care**- Reduced unnecessary treatments, targeted antibiotic use
- **Broader Detection** - Identified rare pathogens previously missed



Impact:

Faster, more accurate diagnosis and stronger infection control.



**Blackpool Teaching
Hospitals**
NHS Foundation Trust



Who We Are

Genetic Signatures is an Australian ASX-listed molecular diagnostics company, specialising in high-throughput syndromic PCR testing for detecting infectious diseases, helping to diagnose earlier, keeping people healthier.

Where We Operate

- Headquartered in Sydney, Australia
- Sales and field service teams in Australia, EMEA and United States
- Channel partners in EMEA & Canada

What We Do


We develop and commercialise rapid, high-throughput PCR tests, powered by our proprietary **3base**[®] technology that streamlines DNA analysis for faster, more accurate results.

We focus on syndromic testing, which is the detection of multiple pathogens that cause similar symptoms in just one single test.



DNA carries a genetic code consisting of 4 chemical bases.

3base[®] is the chemical conversion of cytosine (C) bases into thymine (T) resulting in the conversion of a native 4-base sequence into a 3-base sequence.




Reduces the complexity of the genetic code for reliable diagnosis

Enables efficient pan-screening capabilities for a wide range of infectious diseases


Enables greater resilience to genetic variation

Universal sample extraction process regardless of sample type, compatible with DNA & RNA

Allows for harmonised multiplexed PCR amplification conditions, improving cost efficiency



The 4-base genetic sequence (CGTA) is converted to a 3-base sequence (GTA)





Respiratory



Viral



Bacterial



Enteric



Viral



Bacterial



Parasite





- **FY25 revenue increased 66% to \$14.4m**, delivering standout year on year growth
- **Strong respiratory sales** powered across all quarters
- **Partnered with leading Australian pathology providers** to scale testing capacity to meet winter demand peaks



- **FY25 EMEA revenue up 40% to \$1.5m** fueled by surging demand for enteric products and strong regional execution
- **Enteric sales focus pays off** with **208% year-on-year growth**
- **NHS trusts in the UK adopt our tests** boosting **infection control** and **preventing outbreaks** in high-demand hospital wards
- **Streamlined EMEA operations**, concentrating resources in core markets



- **Expanded go-to-market strategy**, engaging stakeholders – from patients to payers
- **US operations strengthened** with strategic leadership hires and team changes boost performance
- **Sales pipeline progressing**, with steady advancement
- **First US commercial contracts secured**, marking a pivotal milestone



Faster development timelines



Lower development costs



Enhanced automation

A Well-Considered Strategic Pivot

- Secures the most commercially viable path forward



Fresh Market Assessments

- Identified priority syndromic infectious disease areas
- Findings will inform and direct our future focus





- Q1 FY26 sales of \$5.4 million, representing an **increase of 20%**, over the previous quarter and a **15% uplift compared to the prior corresponding period**;
- Quarterly revenue result is the **highest since COVID years**;
- **Revenue contribution from all three regions** with Australia gaining new business from existing customers, EMEA experiencing a 52% increase in Gastrointestinal (GI) testing and US receiving the first commercial order;
- **Second US contract** was signed with an integrated healthcare organisation, marking a key milestone in the US commercial expansion. The first shipment of test kits was delivered in September, with testing expected to commence early in Q2 FY26;
- **A third US contract** with previous customer experience site signed after the close of the quarter;
- **Strong balance sheet with \$28.2m in cash** and term deposits as at 30 September 2025.



Unlock UK Opportunities

Engage NHS leaders to **prioritise infection control** and outbreak prevention, signing at least 4 new accounts.

Leverage data to highlight the **health economic benefits** of implementing the GSS Enteric tests.

Enhance distributor partnerships in non-direct markets to **drive expansion** and capture new opportunities.



Expanded Go-To-Market Strategy

Concentrate commercial efforts on four high-priority U.S. states to maximise market penetration.

Deepen partnerships with KOLs to **elevate visibility and credibility** of the molecular GI Parasite test.

Laser focused **social media campaigns** targeting laboratories, clinicians and patients with GI symptoms to drive engagement and test demand.



Building for the Future

Development of **new automated solution** and state of the art software.

Develop a menu to address emerging diseases where **3base® technology can shine**.

Further enhancements and improvements to workflows for on-market products.

Formal Business of the Meeting





Q&A / Voting Procedure Overview



Consideration of Reports

“To receive and consider the Financial Report, the Directors’ Report and the Independent Auditor’s Report of the Company for the financial year ended 30 June 2025 (Report).”

No resolution is required for this item.

Following consideration of the Reports, the Chair of the Meeting will give Shareholders a reasonable opportunity to ask questions and make comments on the Report.

The Auditors are also present to answer any questions in relation to the Audit.



Resolution 1 – Re-election of Director – Dr Neil Gunn

To consider and, if thought fit, pass the following as an **ordinary resolution**:

“That, Dr Neil Gunn who retires in accordance with clause 6.7 of the Company’s Constitution, having offered himself for election and being eligible, is re-elected as a Director of the Company.”

	FOR	AGAINST	OPEN
Number of Shares	95,186,991	10,532,572	289,179
% of Proxies	89.79%	9.94%	0.27%

Further Information

- The Board (with Dr Gunn abstaining) recommends that Shareholders vote in **FAVOUR** of this resolution.
- The Chair of the Meeting intends to vote undirected proxies in **FAVOUR** of this resolution.



Resolution 2 – Re-election of Director – Ms Caroline Waldron

To consider and, if thought fit, pass the following as an **ordinary resolution**:

“That, Ms Caroline Waldron who retires in accordance with clause 6.7 of the Company’s Constitution, having offered herself for election and being eligible, is re-elected as a Director of the Company.”

	FOR	AGAINST	OPEN
Number of Shares	96,306,561	9,943,807	289,179
% of Proxies	90.40%	9.33%	0.27%

Further Information

- The Board (with Ms Waldron abstaining) recommends that Shareholders vote in **FAVOUR** of this resolution.
- The Chair of the Meeting intends to vote undirected proxies in **FAVOUR** of this resolution.



Resolution 3 – Adoption of the Remuneration Report

To consider and, if thought fit, pass the following as an **ordinary resolution**:

“That, the Company’s Remuneration Report for the financial year ended 30 June 2025, as set out in the Directors’ Report, is adopted.”

	FOR	AGAINST	OPEN
Number of Shares	91,683,737	11,553,875	282,276
% of Proxies	88.57%	11.16%	0.27%

Further Information

- Voting restrictions apply to KMP and their closely related parties.
- The vote on this resolution is advisory only and does not bind the Directors or Company.
- The Chair of the Meeting intends to vote undirected proxies in **FAVOUR** of this resolution.



Resolution 4 – Approval to Grant Restricted Rights to a Director, Ms Anne Lockwood

To consider and, if thought fit, pass the following as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 10.14, and for all other purposes, the issue of 250,000 Restricted Rights under the Genetic Signatures Rights Plan to Ms Anne Lockwood, the terms of which are set out in the Explanatory Memorandum accompanying this Notice, is approved.”

	FOR	AGAINST	OPEN
Number of Shares	93,628,452	12,626,585	282,276
% of Proxies	87.89%	11.85%	0.26%

Further Information

- The Board (with Ms Lockwood abstaining) recommends that Shareholders vote in **FAVOUR** of this resolution.
- The Chair of the Meeting intends to vote undirected proxies in **FAVOUR** of this resolution.



Resolution 5 – Approval to Grant Restricted Rights to a Director, Dr Jenny Harry

To consider and, if thought fit, pass the following as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 10.14, and for all other purposes, the issue of 250,000 Restricted Rights under the Genetic Signatures Rights Plan to Dr Jenny Harry, the terms of which are set out in the Explanatory Memorandum accompanying this Notice, is approved.”

	FOR	AGAINST	OPEN
Number of Shares	93,628,452	12,626,585	282,276
% of Proxies	87.89%	11.85%	0.26%

Further Information

- The Board (with Dr Harry abstaining) recommends that Shareholders vote in **FAVOUR** of this resolution.
- The Chair of the Meeting intends to vote undirected proxies in **FAVOUR** of this resolution.



General Questions



Thank you for your attendance





Contact Us

Allison Rossiter

Chief Executive Officer

E: allison.rossiter@geneticsignatures.com

P: +61 (02) 9870 7580

Karl Pechmann

Chief Financial & Operating Officer &
Joint Company Secretary

E: karl.pechmann@geneticsignatures.com

Visit us

www.geneticsignatures.com

Follow us



Disclaimer



This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It provides general background information about the Company's activities current as at the date of this presentation. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without express consent of GSS.

No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability (whether for negligence, under statute or otherwise) is or will be accepted by the Company or by any of its officers, directors, shareholders, employees or advisers as to or in relation to the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or any omission from this presentation or of any other written or oral information or opinions provided now or in the future to any interested party or its advisers. In particular, no representation or warranty is given as to the achievement or reasonableness of any plans, future projections, management targets, prospects or returns and nothing in this presentation is or should be relied upon as a promise or representation as to the future.

The Company expressly disclaims all liability for any loss or damage of whatsoever kind (whether foreseeable or not) which may arise from any person acting on any information and opinions relating to the Company contained in this presentation or any information which is made available in connection with any further enquiries, notwithstanding any negligence, default or lack of care. In furnishing this presentation, the Company undertakes no obligation to provide any additional information.

Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Company since the date of the presentation.

This presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any or contract or investment decision. This presentation may not be released to US wire services or distributed in the United States. Without limiting the foregoing, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or in other jurisdictions where it would be illegal. The securities of Genetic Signatures have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable US state securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable US state securities laws.

The receipt of this presentation by any person and any information contained herein or subsequently communicated to any person is not to be taken as constituting the giving of investment advice by the Company or any other person to any such person. No such person should expect the Company or any of its officers, directors, shareholders, employees or advisers to owe it any duties or responsibilities and should take its own professional advice. The Recipient must rely solely on its own knowledge, investigation, judgement and assessment of the matters which are the subject of this presentation and to satisfy itself as to the accuracy and completeness.

